Literature DB >> 27401566

Organic Cation Transporter 2 Overexpression May Confer an Increased Risk of Gentamicin-Induced Nephrotoxicity.

Zhibo Gai1, Michele Visentin1, Christian Hiller1, Evelin Krajnc1, Tongzhou Li1, Junhui Zhen2, Gerd A Kullak-Ublick3.   

Abstract

Nephrotoxicity is a relevant limitation of gentamicin, and obese patients have an increased risk for gentamicin-induced kidney injury. This damage is thought to depend on the accumulation of the drug in the renal cortex. Obese rats showed substantially higher levels of gentamicin in the kidney than did lean animals. This study characterized the role of organic cation transporters (OCTs) in gentamicin transport and elucidated their possible contribution in the increased renal accumulation of gentamicin in obesity. The mRNA and protein expression levels of the organic cation transporters Oct2 (Slc22a2) and Oct3 (Slc22a3) were increased in kidney samples from obese mice fed a high-fat diet. Similarly, OCT2 (∼2-fold) and OCT3 (∼3-fold) showed increased protein expression in the kidneys of obese patients compared with those of nonobese individuals. Using HEK293 cells overexpressing the different OCTs, human OCT2 was found to transport [(3)H]gentamicin with unique sigmoidal kinetics typical of homotropic positive cooperativity (autoactivation). In mouse primary proximal tubular cells, [(3)H]gentamicin uptake was reduced by approximately 40% when the cells were coincubated with the OCT2 substrate metformin. The basolateral localization of OCT2 suggests that gentamicin can enter proximal tubular cells from the blood side, probably as part of a slow tubular secretion process that may influence intracellular drug concentrations and exposure time. Increased expression of OCT2 may explain the higher accumulation of gentamicin, thereby conferring an increased risk of renal toxicity in obese patients.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27401566      PMCID: PMC4997869          DOI: 10.1128/AAC.00907-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  49 in total

1.  Trps1 haploinsufficiency promotes renal fibrosis by increasing Arkadia expression.

Authors:  Zhibo Gai; Gengyin Zhou; Ting Gui; Shunji Itoh; Kosuke Oikawa; Kohsaku Uetani; Yasuteru Muragaki
Journal:  J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 10.121

2.  Obesity as a risk factor in drug-induced organ injury. IV. Increased gentamicin nephrotoxicity in the obese overfed rat.

Authors:  G B Corcoran; D E Salazar
Journal:  J Pharmacol Exp Ther       Date:  1989-01       Impact factor: 4.030

Review 3.  Renal organic anion transporters (SLC22 family): expression, regulation, roles in toxicity, and impact on injury and disease.

Authors:  Li Wang; Douglas H Sweet
Journal:  AAPS J       Date:  2012-10-09       Impact factor: 4.009

4.  Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2.

Authors:  Tomohiko Kurata; Yuichi Muraki; Hideki Mizutani; Takuya Iwamoto; Masahiro Okuda
Journal:  Drug Metab Pharmacokinet       Date:  2010       Impact factor: 3.614

Review 5.  New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view.

Authors:  Jose M Lopez-Novoa; Yaremi Quiros; Laura Vicente; Ana I Morales; Francisco J Lopez-Hernandez
Journal:  Kidney Int       Date:  2010-09-22       Impact factor: 10.612

6.  Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.

Authors:  Giuliano Ciarimboli; Dirk Deuster; Arne Knief; Michael Sperling; Michael Holtkamp; Bayram Edemir; Hermann Pavenstädt; Claudia Lanvers-Kaminsky; Antoinette am Zehnhoff-Dinnesen; Alfred H Schinkel; Hermann Koepsell; Heribert Jürgens; Eberhard Schlatter
Journal:  Am J Pathol       Date:  2010-01-28       Impact factor: 4.307

7.  Renal tubular transport of gentamicin in the rat.

Authors:  E Pastoriza-Munoz; R L Bowman; G J Kaloyanides
Journal:  Kidney Int       Date:  1979-10       Impact factor: 10.612

8.  Sex-related differences in the susceptibility of rats to gentamicin nephrotoxicity.

Authors:  W M Bennett; R A Parker; W C Elliott; D N Gilbert; D C Houghton
Journal:  J Infect Dis       Date:  1982-03       Impact factor: 5.226

Review 9.  Association between obesity and kidney disease: a systematic review and meta-analysis.

Authors:  Y Wang; X Chen; Y Song; B Caballero; L J Cheskin
Journal:  Kidney Int       Date:  2007-10-10       Impact factor: 10.612

10.  Effect of sex hormones on gentamicin-induced nephrotoxicity in rats.

Authors:  J C Carraro-Eduardo; A V Oliveira; M E Carrapatoso; J F Ornellas
Journal:  Braz J Med Biol Res       Date:  1993-06       Impact factor: 2.590

View more
  10 in total

Review 1.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

2.  Localization of Xenobiotic Transporters Expressed at the Human Blood-Testis Barrier.

Authors:  Raymond K Hau; Robert R Klein; Stephen H Wright; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2022-03-20       Impact factor: 3.579

3.  Genetic, epigenetic, and environmental mechanisms govern allele-specific gene expression.

Authors:  Celine L St Pierre; Juan F Macias-Velasco; Jessica P Wayhart; Li Yin; Clay F Semenkovich; Heather A Lawson
Journal:  Genome Res       Date:  2022-05-02       Impact factor: 9.438

4.  Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study.

Authors:  Cornelis Smit; Roeland E Wasmann; Marinus J Wiezer; Hendricus P A van Dongen; Johan W Mouton; Roger J M Brüggemann; Catherijne A J Knibbe
Journal:  Pharm Res       Date:  2019-05-30       Impact factor: 4.200

5.  A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients.

Authors:  Cornelis Smit; Roeland E Wasmann; Sebastiaan C Goulooze; Eric J Hazebroek; Eric P A Van Dongen; Desiree M T Burgers; Johan W Mouton; Roger J M Brüggemann; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2019-10       Impact factor: 6.447

Review 6.  Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking.

Authors:  Wei Zou; Birui Shi; Ting Zeng; Yan Zhang; Baolin Huang; Bo Ouyang; Zheng Cai; Menghua Liu
Journal:  Front Pharmacol       Date:  2021-11-29       Impact factor: 5.810

Review 7.  Equine Drug Transporters: A Mini-Review and Veterinary Perspective.

Authors:  Brielle Rosa
Journal:  Pharmaceutics       Date:  2020-11-08       Impact factor: 6.321

Review 8.  Organic Cation Transporters in Human Physiology, Pharmacology, and Toxicology.

Authors:  Sophia L Samodelov; Gerd A Kullak-Ublick; Zhibo Gai; Michele Visentin
Journal:  Int J Mol Sci       Date:  2020-10-24       Impact factor: 5.923

9.  Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function.

Authors:  Cornelis Smit; Anne M van Schip; Eric P A van Dongen; Roger J M Brüggemann; Matthijs L Becker; Catherijne A J Knibbe
Journal:  J Antimicrob Chemother       Date:  2020-11-01       Impact factor: 5.790

10.  The Role of NF-kB in the Downregulation of Organic Cation Transporter 2 Expression and Renal Cation Secretion in Kidney Disease.

Authors:  Chao Han; Juan Zheng; Fengyi Wang; Qingyang Lu; Qingfa Chen; Ankang Hu; Michele Visentin; Gerd A Kullak-Ublick; Zhibo Gai; Lei Chu
Journal:  Front Med (Lausanne)       Date:  2022-01-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.